About The Study: In the NOTIFY-LVH randomized clinical trial, a centralized population health coordinator–led notification and clinical support pathway for individuals with left ventricular hypertrophy on prior echocardiograms increased the initial treatment of hypertension. This work highlights the potential benefit of leveraging preexisting but potentially underutilized cardiovascular data to improve health care delivery through mechanisms augmenting the traditional ambulatory care system.

While everyone’s heart has an exact chronological age, it also has a ‘biological’ age associated with how well it is functioning. 

Researchers have used data from almost half a million standard 12-lead electrocardiograms (ECG) to create an algorithm to predict the heart’s biological age 

Modelling from the study showed that biological heart age exceeding chronological age by 7 years increased risk of all-cause mortality by 62% and doubled the risk of major adverse cardiovascular adverse (MACE). 

Technology could be used to identify individuals with higher biological heart age and target them for intensive interventions 

Osaka Metropolitan University physicists present a case study of the critical phenomena around Argyres-Douglas singularity of N = 2 susy made at (𝐴₁, 𝐴_4𝑘−1), 𝑘=1,2 realized by one unitary matrix model.

About The Study: Among patients with heart failure with mildly reduced ejection fraction/heart failure with preserved ejection fraction in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure randomized clinical trial, higher proportions of cardiovascular and overall mortality in those with ejection fraction less than 50% were related principally to higher proportions of sudden death. A clear treatment effect of finerenone on cardiovascular or cause-specific mortality was not identified, although the trial was likely underpowered for these outcomes.

About The Study: In this unblinded randomized clinical trial, prothrombin complex concentrate had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring coagulation factor replacement for bleeding during cardiac surgery.